MTRIHealthcare · BiotechnologyTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 31 of 100 as at 13 Nov 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Mentari Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (94): Reported profit is backed by cash, and the company is not expanding recklessly.
Volatility (4): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on MTRI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Nov 2026 | Jefferies | Initiates | Buy | — |
| 10 Nov 2026 | Stifel | Initiates | Buy | — |
| 22 Dec 2021 | HC Wainwright & Co. | Initiates | Buy | — |
| 29 Nov 2021 | HC Wainwright & Co. | Initiates | Buy | — |
| 16 Feb 2021 | Roth Capital | Maintains | Buy | $12 → $12 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
MTRI appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 13 Nov 2026, Mentari Therapeutics, Inc. returned +2.8% against +13.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 51% of US stocks
Cheaper than 59% of US stocks
Cheaper than 11% of US stocks
Cheaper than 85% of US stocks
Higher than 1% of US stocks
Higher than 1% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 6% of US stocks
Higher than 4% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Mentari Therapeutics, Inc. has a market value of $1.1B and an enterprise value of $0.0.
Revenue in the twelve months to 30 June 2026: $1.9M. The latest quarter shrank 100.0% year on year.
Net income over the same four quarters: −$12.6M, a −647.4% net margin.
Free cash flow in the twelve months to 30 June 2026: −$8.6M.
Trailing P/E: 12.5×; forward P/E: −2.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Mentari Therapeutics, Inc. employs 2 people — $970K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Mentari Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Mentari Therapeutics announced that members of its management team will participate in investor conferences in November. The company is a clinical-stage biotechnology company developing therapies for migraine prevention.
Why it matters — The appearances provide MTRI watchers with opportunities to hear from company management.
InMed Pharmaceuticals announced that it completed its merger with privately held Mentari Therapeutics and changed its name to Mentari Therapeutics, Inc. The combined company is expected to begin Nasdaq trading as MTRI on November 9, 2026.
Why it matters — INM watchers should note the company’s name and ticker are changing following the merger.
InMed said its merger with Mentari Therapeutics is expected to close on November 6, 2026, subject to remaining closing conditions. Before the merger is completed, the company expects to redomesticate from British Columbia to Nevada; the headline says trading is expected under the Mentari name and ticker MTRI.
Why it matters — INM watchers should note the anticipated merger closing, corporate redomestication, and change in company name and Nasdaq ticker.
InMed Pharmaceuticals reported that shareholders voted on the matters presented at its 2026 annual general and special meeting. The company is now Mentari Therapeutics, Inc.; the excerpt does not specify the vote outcomes or details of the share consolidation.
Why it matters — INM watchers may note the company’s announced name change and that meeting matters were put to a shareholder vote, while the excerpt provides no specific results.
InMed Pharmaceuticals reported financial results for the first quarter of fiscal 2027, ended September 30, 2026, and provided a corporate update. The company said its full financial statements and related MD&A are available on its website and regulatory filing sites.
Why it matters — INM watchers can review the company’s quarterly financial statements and management discussion for details on its results and corporate update.
Of the 1 analysts covering Mentari Therapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Mentari Therapeutics, Inc. 31 out of 100 across roughly 4,600 US stocks as at 13 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 13 Nov 2026, Mentari Therapeutics, Inc. ranks 31 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (94 of 100).
No analyst covering Mentari Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MTRI are extrapolating price history, which says nothing about the business.
Mentari Therapeutics, Inc. returned +2.8% over the 12 months to 13 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Mentari Therapeutics, Inc., a biotechnology company, develops and provides therapies for migraine prevention. The company's products include MT-001, an anti-PACAP monoclonal antibody designed for convenient subcutaneous dosing; MT-002, an anti-CGRP; and anti-PACAP bispecific antibody designed to inhibit these complementary pathways.
The most recent item we track (GlobeNewsWire, 9 Nov 2026): "Mentari Therapeutics to Present at Upcoming Investor Conferences". Mentari Therapeutics announced that members of its management team will participate in investor conferences in November. The company is a clinical-stage biotechnology company developing therapies for migraine prevention.
Mentari Therapeutics, Inc., a biotechnology company, develops and provides therapies for migraine prevention. The company's products include MT-001, an anti-PACAP monoclonal antibody designed for convenient subcutaneous dosing; MT-002, an anti-CGRP; and anti-PACAP bispecific antibody designed to inhibit these complementary pathways. The company was incorporated in 2025 and is based in Sacramento, California.
CEO Mr. Gregory J. Divis Jr. · 2 employees · United States · https://www.mentaritx.com
